Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879590 | 1.00 | GSK3B (0.45) | GSK3BTDP1L3MBTL1CA1CA2 | |
| SCHEMBL29119424 | 0.87 | ALDH1A1 (0.44) | TDP1CA1CA2ALDH1A1MAPT | |
| SCHEMBL11049883 | 0.85 | ESR1 (0.55) | ALDH1A1MAPTESR1SLC6A3MEN1 | |
| SCHEMBL19357469 | 0.85 | ALDH1A1 (0.47) | RAB9AALDH1A1MAPTESR1 | |
| SCHEMBL19357468 | 0.85 | ALDH1A1 (0.47) | RAB9AALDH1A1MAPTESR1 | |
| SCHEMBL17387472 | 0.84 | HTT (0.41) | GSK3BL3MBTL1CA1CA2ALDH1A1 | |
| SCHEMBL17387473 | 0.84 | HTT (0.41) | GSK3BL3MBTL1CA1CA2ALDH1A1 | |
| SCHEMBL27352443 | 0.81 | NR1I2 (0.59) | GSK3BCA1CA2RAB9AESR1 | |
| SCHEMBL226431 | 0.81 | NR1I2 (0.59) | GSK3BCA1CA2RAB9AESR1 | |
| SCHEMBL947272 | 0.75 | FFAR1 (0.50) | RAB9AMAPTESR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| EP-1554246-B1 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| EP-1554246-A2 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | Bayer HealthCare AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004020410-A2 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | GSK3B 2024/4885TDP1 4031/4885L3MBTL1 4385/4885 |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | SERPINB1, ELANE, MPO | GSK3B 4418/4885TDP1 2339/4885L3MBTL1 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.